Nhanganyaya
Tirzepatide, yakagadziridzwa naEli Lilly, mushonga wepeptide unomiririra chiitiko chakakosha mukurapa chirwere cheshuga chechipiri uye kufutisa. Kusiyana nechinyakare GLP-1 (glucagon-like peptide-1) agonists, Tirzepatide inoshanda pazvose GIP (glucose-inotsamira insulinotropic polypeptide)uyeGLP-1 receptors, achizviwanira zita rekuti amaviri receptor agonist. Iyi nzira mbiri inogonesa kushanda kwepamusoro mukudzora glucose yeropa uye kuderedza uremu hwemuviri, kunyanya kune varwere vane Type 2 chirwere cheshuga uye kufutisa.
Nzira Yekuita
-
GIP receptor activation: Inowedzera insulin secretion uye inovandudza glucose kushivirira.
-
GLP-1 receptor activation: Inosimudzira kuburitswa kwe insulin, inodzvanya glucagon secretion, uye inononoka kubuda mudumbu.
-
Dual synergy: Inopa inoshanda glycemic control uye yakakosha kuderedza uremu.
Clinical Data Analysis
1. SURPASS Miyedzo (Type 2 Diabetes)
Kupfuura akawandaSURPASS miedzo yekiriniki, Tirzepatide yakapfuura insulini uye Semaglutide mu glycemic uye kuderedza uremu migumisiro.
| Boka revarwere | Dose | Avg. HbA1c kuderedza | Avg. Kuderedza uremu |
|---|---|---|---|
| Type 2 Chirwere cheshuga | 5 mg | -2.0% | -7.0 kg |
| Type 2 Chirwere cheshuga | 10 mg | -2.2% | -9.5 kg |
| Type 2 Chirwere cheshuga | 15 mg | -2.4% | -11.0 kg |
➡ Kuenzaniswa neSemaglutide (1 mg: HbA1c -1.9%, Weight -6.0 kg), Tirzepatide yakaratidza migumisiro yepamusoro mune zvose glycemic control uye kuora kurasikirwa.
2. SURMOUNT Miedzo (Obesity)
Muvarwere vakafuta vasina chirwere cheshuga, Tirzepatide yakaratidza kushamisa-kurasikirwa kwehuremu.
| Dose | Avg. Kuderedza uremu (mavhiki 72) |
|---|---|
| 5 mg | -15% |
| 10 mg | -20% |
| 15 mg | -22.5% |
➡ Kune murwere anorema 100 kg, yakakwira-dose Tirzepatide inogona kuwana kuderedzwa kwehuremu22.5 kg.
Hunhu Hunokosha
-
Dual mechanism: Kupfuura single GLP-1 agonists.
-
Superior efficacy: Inoshanda mune zvese glycemic control uye uremu manejimendi.
-
Wide applicability: Inokodzera zvose chirwere cheshuga uye kufutisa.
-
Kukwanisa kwemusika wepamusoro: Kuwedzera kudiwa kwekufutisa kurapwa zvinzvimbo Tirzepatide senge remangwana blockbuster mushonga.
Market Outlook
-
Market size forecast: Pakazosvika 2030, musika wepasi rose weGLP-1 wemishonga unofungidzirwa kuti uchapfuuraUSD 150 bhiriyoni, Tirzepatide ingangotora chikamu chikuru.
-
Competitive landscape: Mukwikwidzi mukuru ndiNovo Nordisk's Semaglutide (Ozempic, Wegovy).
-
Advantage: Clinical data inoratidza Tirzepatide inopa kurasikirwa kwehuremu hwepamusoro kana ichienzaniswa neSemaglutide, ichisimbisa kukwikwidza kwayo kwemusika mukurapa kufutisa.
Nguva yekutumira: Sep-12-2025